3Chopt Investment Partners LLC Takes $1.03 Million Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

3Chopt Investment Partners LLC acquired a new position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 1,250 shares of the biopharmaceutical company’s stock, valued at approximately $1,027,000.

Several other large investors have also bought and sold shares of the business. NewSquare Capital LLC increased its holdings in shares of Regeneron Pharmaceuticals by 1,450.0% during the first quarter. NewSquare Capital LLC now owns 31 shares of the biopharmaceutical company’s stock worth $25,000 after buying an additional 29 shares in the last quarter. Sunbelt Securities Inc. bought a new position in Regeneron Pharmaceuticals in the first quarter valued at about $25,000. Steward Financial Group LLC acquired a new stake in shares of Regeneron Pharmaceuticals during the fourth quarter valued at about $28,000. Householder Group Estate & Retirement Specialist LLC grew its holdings in shares of Regeneron Pharmaceuticals by 1,750.0% during the first quarter. Householder Group Estate & Retirement Specialist LLC now owns 37 shares of the biopharmaceutical company’s stock worth $30,000 after purchasing an additional 35 shares during the last quarter. Finally, Manchester Capital Management LLC increased its stake in shares of Regeneron Pharmaceuticals by 740.0% in the first quarter. Manchester Capital Management LLC now owns 42 shares of the biopharmaceutical company’s stock valued at $35,000 after buying an additional 37 shares during the period. 84.15% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of equities research analysts have weighed in on the stock. Royal Bank of Canada boosted their target price on shares of Regeneron Pharmaceuticals from $820.00 to $830.00 and gave the stock a “sector perform” rating in a report on Monday, August 21st. 500.com reaffirmed a “maintains” rating on shares of Regeneron Pharmaceuticals in a research report on Wednesday, June 28th. Guggenheim reduced their price target on Regeneron Pharmaceuticals from $935.00 to $900.00 in a research report on Monday, July 17th. Canaccord Genuity Group raised Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating and increased their price target for the company from $720.00 to $992.00 in a research note on Monday, August 21st. Finally, Barclays lifted their price objective on Regeneron Pharmaceuticals from $900.00 to $925.00 and gave the stock an “overweight” rating in a research note on Monday, August 21st. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and twenty have issued a buy rating to the company’s stock. According to data from MarketBeat, Regeneron Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus target price of $903.27.

Regeneron Pharmaceuticals Stock Performance

Shares of Regeneron Pharmaceuticals stock traded up $1.84 during mid-day trading on Wednesday, hitting $834.61. 17,377 shares of the stock were exchanged, compared to its average volume of 593,151. Regeneron Pharmaceuticals, Inc. has a 12 month low of $668.00 and a 12 month high of $847.50. The company has a 50-day simple moving average of $776.92 and a 200 day simple moving average of $773.36. The company has a market capitalization of $90.60 billion, a P/E ratio of 22.01, a P/E/G ratio of 2.45 and a beta of 0.19. The company has a debt-to-equity ratio of 0.11, a quick ratio of 4.64 and a current ratio of 5.45.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its earnings results on Thursday, August 3rd. The biopharmaceutical company reported $10.24 earnings per share (EPS) for the quarter, beating the consensus estimate of $8.48 by $1.76. The firm had revenue of $3.16 billion during the quarter, compared to analyst estimates of $3.02 billion. Regeneron Pharmaceuticals had a return on equity of 19.19% and a net margin of 33.93%. The business’s revenue was up 10.5% compared to the same quarter last year. During the same period last year, the firm posted $9.77 EPS. Sell-side analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.42 earnings per share for the current fiscal year.

Insider Buying and Selling at Regeneron Pharmaceuticals

In other news, CFO Robert E. Landry sold 223 shares of the firm’s stock in a transaction that occurred on Wednesday, August 23rd. The shares were sold at an average price of $844.00, for a total transaction of $188,212.00. Following the completion of the sale, the chief financial officer now owns 31,699 shares in the company, valued at approximately $26,753,956. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. In related news, EVP Marion Mccourt sold 250 shares of the business’s stock in a transaction on Monday, July 3rd. The stock was sold at an average price of $710.09, for a total transaction of $177,522.50. Following the sale, the executive vice president now directly owns 20,303 shares in the company, valued at approximately $14,416,957.27. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CFO Robert E. Landry sold 223 shares of the stock in a transaction dated Wednesday, August 23rd. The stock was sold at an average price of $844.00, for a total transaction of $188,212.00. Following the completion of the sale, the chief financial officer now directly owns 31,699 shares in the company, valued at $26,753,956. The disclosure for this sale can be found here. Insiders have sold a total of 32,521 shares of company stock worth $27,232,176 over the last three months. 8.83% of the stock is currently owned by insiders.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat neovascular age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.